Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca And Huma On Digital’s Value For Pharma

Executive Summary

Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.

You may also be interested in...



Speaking To Mobiquitiy About The Whats And Hows For Digital Platforms

Health care is undergoing a transformation as more and more treatments become partially-digitized. However, building the platforms required is difficult, meaning many companies call for third-party help. Medtech Insight spoke to one player in this space, Mobiquity, to learn more about the process.

Chapter 11 Bankruptcy, Not A Party You Would Want An Invitae For

Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.

Freenome Bags Another $254m As Study Results Draw Closer

Freenome, the Roche-backed early cancer detection liquid biopsy developer has raised yet more money, making it one of the best-funded companies in its sub-sector. With trial results due relatively soon, investors are likely hoping this will be the last funding round required before full commercialization.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel